Follow-up of the soft tissue sarcoma patient

Background.Although the survival of children with soft tissue sarcoma (STS) has improved considerably, the outcome of patients with metastatic disease, and those with primary tumours of the extremities or parameningeal sites remains disappointing. We describe the clinical outcome of an ifosfamide-based regimen with local therapy directed only to children who failed to achieve a complete response to initial chemotherapy.Patients and Methods.Twenty-one children with STS (16 rhabdomyosarcoma) who presented with unresectable tumours were treated with five courses of ifosfamide (9 g/m2) and etoposide (600 mg/m2). Patients who did not achieve a complete response then received local therapy. Chemotherapy with ifosfamide combined with etoposide, vincristine (1.5 mg/m2and doxorubicin (60 mg/m2) or vincristine and actinomycin D (1.5 mg/m2) was continued for one year.Results and Discussion.Objective responses to five courses of ifosfamide and etoposide were seen in all patients. Disease free survival (DFS) at a median follow up of 59 months was 57% (95% CI 29–75%). The DFS of children who received local therapy was 89% compared with 33% in those who received chemotherapy alone (p=0.027). Locoregional recurrences did not occur in children who received radiotherapy to the site of the primary tumour. Ifosfamide-based chemotherapy does not reduce the incidence of loco-regional recurrence in children who do not receive local therapy.

Download Full-text

P-268 Surgical outcomes and strict follow-up of retroperitoneal soft-tissue sarcoma

Annals of Oncology ◽

10.1093/annonc/mdw199.258 ◽

2016 ◽

Vol 27 ◽

pp. ii77

Author(s):

A. Chiappa ◽

E. Bertani ◽

A. Zbar ◽

D. Foschi ◽

F. Luca ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Surgical Outcomes ◽

Retroperitoneal Soft Tissue Sarcoma

Download Full-text

Stereotactic Body Radiotherapy for Metastatic and Recurrent Soft Tissue Sarcoma

10.21203/rs.3.rs-122172/v1 ◽

2020 ◽

Author(s):

Xiaoyao Feng ◽

Jing Li ◽

Aomei Li ◽

Han Zhou ◽

Xixu Zhu ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Survival Rates ◽

Progression Free Survival ◽

Hematogenous Metastasis ◽

Invasive Growth ◽

Free Survival ◽

Grade 3 ◽

Clinical Transformation

Abstract BackgroundSoft tissue sarcoma（STS） is a malignant tumor of highly heterogeneous mesenchymal origin. STS has a biologic pattern and clinical transformation with localized invasive growth and susceptibility to hematogenous metastasis. Metastatic and recurrent soft tissue sarcoma may be treated by local therapeutic options, including surgery and radiation therapy. This study evaluated the safety and efficacy of SBRT for metastatic and recurrent soft tissue sarcoma.MethodsWe performed a retrospective analysis of 37 STS patients with 58 lesions treated with SBRT from 2009-2019 at our institution. We analyze the local control (LC), overall survival (OS), progression free survival (PFS) and toxicity rates of the patients.ResultThe median follow-up was 20 months（range 2 to 120 months）. One and two year LC rates were 75.3% and 55.2% [95% confidence interval (CI) 20–25 months]. Median OS was 24 months and the survival rates were 66.6%, 45% and 26.6% at 1, 2 and 3-year after SBRT. Median PFS were 11months (95% CI 8–18 months). No acute or chronic grade ≥ 3 toxicity was observed.ConclusionsIn patients with metastatic and recurrent STS, LC, OS and PFS were higher than expected. SBRT should be a proper treatment option for STS.

Download Full-text